F. André Et Al. , "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial," The Lancet , vol.401, no.10390, pp.1773-1785, 2023
André, F. Et Al. 2023. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. The Lancet , vol.401, no.10390 , 1773-1785.
André, F., Hee Park, Y., Kim, S., Takano, T., Im, S., Borges, G., ... Lima, J. P.(2023). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. The Lancet , vol.401, no.10390, 1773-1785.
André, Fabrice Et Al. "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial," The Lancet , vol.401, no.10390, 1773-1785, 2023
André, Fabrice Et Al. "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial." The Lancet , vol.401, no.10390, pp.1773-1785, 2023
André, F. Et Al. (2023) . "Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial." The Lancet , vol.401, no.10390, pp.1773-1785.
@article{article, author={Fabrice André Et Al. }, title={Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial}, journal={The Lancet}, year=2023, pages={1773-1785} }